Publication details

Kompenzují nové léky vliv cytogenetických negativních prognostických faktorů? Aktualizované výsledky o rok později

Title in English Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? Actual results - a year later.
Authors

ZAORALOVÁ Romana GREŠLIKOVÁ Henrieta FILKOVÁ Hana NĚMEC Pavel SMETANA Jan BERÁNKOVÁ Kristina KUGLÍK Petr KUPSKÁ Renata OLTOVÁ Alexandra POUR Luděk KŘIVANOVÁ Andrea KREJČÍ Marta ADAM Zdeněk SMEJKALOVÁ Jana HÁJEK Roman

Year of publication 2008
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description In this study we have focusede to impact of five chromosomal changes - el(13)(q14) - RB1 gene, t(4;14), del(17)(p13) - p53 gene, gain (1)(q21) - CKS1B gene and hyperdiploidy in relapsed multiple myeloma patients. We have prooved, that Velcade in combined therapy overcomes the negative impact of gain (1)(q21) in our group of 74 patients and both the new drugs, Velcade and thalidomide, overcomes the potentional negative impact of all other changes.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info